Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Conversation logo

A long day in the office can leave you empty of energy and overcome with desire for TV and a takeaway. But you’ve been sitting down all day. So why do you feel as tired as your friends who have physical jobs?

Struggling through your list of essential tasks feels ever more gruelling as the clock ticks down for home-time. Worse still is bumping into a colleague on your way out who “just wants a quick minute”. It might seem obvious that you are more likely to make impulsive decisions at the end of a long day, but people often power through anyway.

A recent study that scanned people’s brains at different points in their work day found high-demand tasks which require intense, constant concentration can lead to build-up of a potentially toxic chemical called glutamate. Normally used to send signals from nerve cells, in large quantities glutamate alters the performance of a brain region involved in planning and decision making, the lateral prefrontal cortex (lPFC).

Science has shown time again that mental fatigue has real effects. There are numerous studies which show that court decisions can depend on how fatigued the judge is. For example, after a long day in court, judges are more likely to deny parole (which is considered the safer option). Studies show that clinicians are more likely to prescribe unnecessary antibiotics at the end of a tiring clinical session.

Read the full article on The Conversation website, written by Professor Zoltan Molnar, (Department of Physiology, Anatomy and Genetics, University of Oxford) and Professor Tamas Horvath (Yale University).

Oxford is a subscribing member of The Conversation. Find out how you can write for The Conversation.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.